Introduction
Changes in medical practice are not made in decisive steps. Rather the pendulum swings, its middle point reflecting the changes, but the extremes of its traverse determined by the first enthusiasm of discovery and the subsequent reaction. So with clinical trials, the revolution in which double blind, controlled studies replaced the experience of great physicians as a guide to therapy has been followed by the realization that such studies can also be fallacious. In this paper, we present evidence that double blind trials may not be double blind and suggest that there are situations in which double blind trials may be misleading and should be avoided.
Methods
Eighteen patients with definite or classical rheumatoid arthritis by the A.R.A. criteria took part in a crossover trial comparing aspirin (3.6 g daily), a new anti-inflammatory agent, not at present available in Britain at the time of writing, and placebo. Each treatment was given for 2 weeks. All treatments were supplied in identical capsules.
Two experienced measurement technicians made routine clinical measurements and recorded side effects at the end of each week. After the assessment, and again when the study had been completed, the technicians were asked to guess which treatment the patient had been receiving, and to state their reasons.
Results
Sixteen patients completed the study, providing forty-eight treatment periods and sixteen complete sequences. The identification rates are shown in Table 1 ; such high rates are very unlikely to have occurred by chance. Table 2 shows that aspirin was more likely and the unknown drug less likely to be correctly identified. Reasons for identification are shown in Table 3 .
Discussion
It is the observer who should be kept in ignorance of the nature of a treatment being assessed; the patient is unlikely to be biased unless he is given a treatment which he recognizes. If the observer becomes aware of the nature of the treatment, the (Huskisson, 1974) . Injections have a greater placebo effect than tablets (Traut & Passarelli, 1957) , and the placebo effect may be increased by increasing the number of tablets prescribed. In many trials, double blindness is unnecessary, and in some it is actually misleading. It has been routine practise in trials carried out at the London Hospital to ensure the maintenance of double blindness in trials by asking the physician to guess which treatment a patient is receiving (Mason, 1975, personal communication) . In a trial of immunosuppressives and gold, treatment was correctly identified in only two of one-hundred and twenty-one patients (Currey, Harris, Mason, Woodland, Beveridge, Roberts, Vere, Dixon, Davies & Owen-Smith, 1974) ; it is difficult to imagine that such a low rate of identification would be achieved in trials of drugs with more characteristic side effects such as D-penicillamine.
